ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
NCT02681523
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
8
Enrollment
OTHER
Sponsor class
Stopped
Slow patient recruitment
Conditions
Breast Cancer
Interventions
DRUG:
Eribulin
Sponsor
Imperial College London